201 related articles for article (PubMed ID: 29643290)
1. [Screening for colorectal cancer using immunological fecal occult blood test in inpatients].
Kawabata H; Inoue N; Kawakatsu Y; Okazaki Y; Hitomi M; Miyata M; Motoi S
Nihon Shokakibyo Gakkai Zasshi; 2018; 115(4):377-384. PubMed ID: 29643290
[TBL] [Abstract][Full Text] [Related]
2. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
3. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of self-checked fecal occult blood testing for colorectal cancer in Thai patients.
Lohsiriwat V
Asian Pac J Cancer Prev; 2014; 15(18):7981-4. PubMed ID: 25292099
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
[TBL] [Abstract][Full Text] [Related]
6. Fecal occult blood test in colorectal cancer screening.
Li JN; Yuan SY
J Dig Dis; 2019 Feb; 20(2):62-64. PubMed ID: 30714325
[TBL] [Abstract][Full Text] [Related]
7. A Clinician's Guide to Fecal Occult Blood Testing for Colorectal Cancer.
Bechtold ML; Ashraf I; Nguyen DL
South Med J; 2016 Apr; 109(4):248-55. PubMed ID: 27043809
[TBL] [Abstract][Full Text] [Related]
8. Use and abuse of fecal occult blood tests: a community hospital experience.
Soin S; Akanbi O; Ahmed A; Kim Y; Pandit S; Wroblewski I; Saleem N
BMC Gastroenterol; 2019 Sep; 19(1):161. PubMed ID: 31481027
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Screening Using Fecal Occult Blood Testing and Colonoscopy on the Risk of Colorectal Cancer: The Japan Public Health Center-based Prospective Study.
Tanaka K; Sobue T; Zha L; Kitamura T; Sawada N; Iwasaki M; Inoue M; Yamaji T; Tsugane S
J Epidemiol; 2023 Feb; 33(2):91-100. PubMed ID: 34053963
[TBL] [Abstract][Full Text] [Related]
10. The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening.
Hubbard RA; Johnson E; Hsia R; Rutter CM
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1612-9. PubMed ID: 23868091
[TBL] [Abstract][Full Text] [Related]
11. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
[TBL] [Abstract][Full Text] [Related]
12. Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study.
Wei SC; Tsao PN; Wang YT; Lin BR; Wu DC; Tsai WS; Chen JS; Wong JM
Cancer Med; 2019 Jul; 8(7):3583-3591. PubMed ID: 31063258
[TBL] [Abstract][Full Text] [Related]
13. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
14. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
[TBL] [Abstract][Full Text] [Related]
15. Immunological fecal occult blood test vs. serum ferritin for detection of colorectal neoplasia in high risk asymptomatic population.
Sobrino-Cossío S; Fenocchi E; Hernández-Guerrero A; Alonso-Lárraga JO; De la Mora-Levy JG; Larracilla-Salazar I
Rev Gastroenterol Mex; 2011; 76(3):191-8. PubMed ID: 22041307
[TBL] [Abstract][Full Text] [Related]
16. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
[TBL] [Abstract][Full Text] [Related]
17. Trends in colonoscopy and fecal occult blood test use after the introduction of dual screening offers in Germany: Results from a large population-based study, 2003-2016.
Chen C; Stock C; Jansen L; Chang-Claude J; Hoffmeister M; Brenner H
Prev Med; 2019 Jun; 123():333-340. PubMed ID: 30946858
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
[TBL] [Abstract][Full Text] [Related]
19. Screening for Colorectal Cancer Is Associated With Lower Disease Stage: A Population-Based Study.
Kubisch CH; Crispin A; Mansmann U; Göke B; Kolligs FT
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1612-1618.e3. PubMed ID: 27085763
[TBL] [Abstract][Full Text] [Related]
20. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
